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Intracellular signaling is often mediated by a family of functionally overlapping signal mediators that contain
multiple sites interacting with other proteins or ligands with weak affinity (Kd > mM). Conjugation of multiple
low-affinity ligands into a high-affinity multivalent molecule provides a means to control the entire protein
family within a single intracellular pathway. The N-end rule pathway is a ubiquitin (Ub)-dependent proteolytic
systemwhere at least four Ub ligases, called N-recognins, have a common domain critical for binding to type
1 (basic) and type 2 (bulky hydrophobic) destabilizing N-terminal residues of substrates as degrons. The
recent development of a heterodivalent inhibitor targeting type 1 and type 2 substrate binding sites of the
N-recognin family provides new opportunities to manipulate this proteolytic pathway in biochemical and
pathophysiological conditions. We overview the N-end rule pathway as an intracellular target for heterodiva-
lent molecules and discuss the basis of thermodynamics and kinetics related to heterodivalent interactions.Introduction
Nature employs multivalent interactions to increase selectivity
and avidity of protein-protein or protein-ligand interactions in
various processes, such as antigen-antibody, virus-cell, and
bacterial toxin-cell interactions (Choi, 2004; Kiessling et al.,
2000, 2006; Huskens, 2006; Basha et al., 2006). Examples of
natural multivalent molecules include the trimeric hemagglutinin
complex of the influenza virus that recognizes host cells through
multivalent binding to N-acetyl neuraminic acid (Spaltenstein
and Whitesides, 1991). The enhancement, often dramatic, in
selectivity and avidity of multivalent interaction is manifested
by synthetic multivalent sialic acid molecules capable of binding
to the hemagglutinin receptor on the viral surface with a multiva-
lent enhancement factor of greater than 107 (Choi et al., 1996). As
such, natural and synthetic multivalent interactions have been
extensively investigated to explain the basis of multivalency
and in an attempt to inhibit undesired ligand-receptor interac-
tions or to induce desired biological responses. Various
synthetic multivalent compounds were proven to be able to effi-
ciently control physiological processes in different contexts,
including receptor clustering (Gestwicki and Kiessling, 2002;
Alarco´n et al., 2006; Dam and Brewer, 2008), receptor selectivity
(Lee and Lee, 2000), bacterial toxins (Rai et al., 2006; Kitov et al.,
2000), pathogen-cell adhesion (Matrosovich, 1989), and protein-
protein interactions (Gestwicki and Marinec, 2007). Most of the
multivalent molecules synthesized to date are interhomovalent
(Figure 1A) in that two identical ligands target the same binding
site of two identical proteins on the surface of viruses, bacteria,
or cells (reviewed in Choi, 2004). In contrast, rapamycin, an
immunosuppressant drug produced from the bacteriumStrepto-
myces hygroscopicus, is an interheterodivalent compound
(Figure 1B) that can simultaneously bind two cytoplasmicChemistry & Bioloproteins, FKBP12 (FK506 binding protein) and FRB (FKBP-rapa-
mycin binding domain), to form the FKBP-rapamycin-FRB
ternary complex (Sabatini et al., 1994). Some synthetic rapamy-
cin derivatives were demonstrated to alter various intracellular
pathways, including protein relocalization (de Graffenried et al.,
2004; Haruki et al., 2008), conditional induction of apoptosis
(Mallet et al., 2002), protein degradation (Janse et al., 2004),
and conditional protein splicing (Schwartz et al., 2007).
Intracellular signaling is often mediated by a family of function-
ally overlapping signal mediators that contain one or more struc-
turally conserved domain(s) interacting with other ligands or
proteins. Protein-protein and ligand-protein interactions are
the combined effect of multiple microscopic interactions, such
as electrostatic interactions between amino acids and van der
Waals interactions between atoms. The communication
between many signaling molecules is governed by weak, tran-
sient interactions (Kd > mM), as opposed to high-affinity drug-
receptor interactions estimated to have mean Kd of 10
7.3 M
(Houk et al., 2003). Not surprisingly, the paradigm in drug
discovery has been focused on screening or synthesizing the
highest-affinity ligand (Kd, submicromolar or nanomolar) on the
hopes that the resulting ligand will lead to a druggable
compound with maximal therapeutic and minimal side effects.
Under this paradigm, weak-affinity molecules are neglected
based on a general notion that a weak-affinity molecule binds
to a target with low selectivity and, thus, is pharmacologically
useless. It is increasingly clear, however, that many weak-affinity
biological interactions can become a useful target when multiple
low-affinity ligands are combined into a multivalent molecule.
For instance, various compounds with tethered ligands have
been designed to enhance affinity for target enzymes (reviewed
in Erlanson et al., 2004), such as carbonic anhydrase I (Banerjeegy 16, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 121
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thrombin (Tolkatchev et al., 2005). The concept of multivalency
is also successfully used in fragment-based drug discovery
(FBDD), where a functional drug with high affinity and selectivity
is synthesized or screened in smaller pieces that have low
affinity and selectivity (Congreve et al., 2008). In this approach,
initial high throughput screening identifies simple molecular
fragments, which usually are small (120–250 Da) and of weak
affinity (Kd, 10 mM to millimolar). However, some of the resulting
fragment hits may have high unit affinity per atom, and the
combination of these monovalent molecules may yield a drug-
like compound with high selectivity and affinity to the target,
thermodynamically (enhanced binding affinity) and kinetically
(reduced dissociation rate). One noteworthy technique based
on the concept of FBDD is ‘‘SAR by NMR’’ (structure-activity
relationships by nuclear magnetic resonance), in which multiple
small fragments that bind to proximal sites on a protein are
screened and linked together using NMR-assisted structural
analysis (Shuker et al., 1996; Hajduk, 2006; Weigelt et al.,
2002). Bearing in mind the demonstrated effectiveness of multi-
valency in various interactions, one would speculate that a multi-
valent molecule targeting multiple sites within a single domain or
of multiple domains conserved in signaling molecules would
enable the control of the entire protein family within a specific
intracellular signaling pathway.
The purpose of this review is to overview the N-end rule
pathway as an intracellular target for heterodivalent molecules,
introduce the design and characterization of model heterodiva-
lent compounds, and discuss the basis of thermodynamics
and kinetics related to multivalent molecules, in particular
those with long, flexible linkers. The N-end rule pathway is
a ubiquitin (Ub)-dependent proteolytic system that plays a crit-
ical role in a variety of physiological processes, including
cardiovascular signaling, oxygen/nitric oxide sensing, and viral
and bacterial life cycles (Tasaki and Kwon, 2007). There are
at least four recognition E3 components, called N-recognins,
that contain a common domain critical for binding to type 1
(basic) and type 2 (bulky hydrophobic) destabilizing N-terminal
Figure 1. Different Types of Multivalent
Ligands and a Model Showing the Influence
of the Linker on Effective Concentrations of
Divalent Molecules
(A–C) Shown are interhomovalent (A), interhetero-
valent (B), and intraheterovalent (C) molecules.
(D–F) The bound ligand in a divalent molecule
confines the other ligand to the hemispherical
proximity, influencing the effective concentration
(Ceff) as a function of its linker length. Shown are
RF-Cn-type molecules (see below), in which the
linker is longer (D), optimal (E), or shorter (F)
compared with the distance between two binding
sites of the target.
residues of substrates as degrons.
Recent development of a heterodivalent
inhibitor targeting type 1 and type 2
substrate binding sites of the N-recog-
nin family provides new opportunities
to manipulate this proteolytic pathway
in biochemical and pathophysiological conditions (Lee et al.,
2008).
Multivalent Interaction: Thermodynamics And Kinetics
We discuss thermodynamics and kinetics related to heterodiva-
lent molecules (Figure 1) that have a long, flexible linker to simul-
taneously target type 1 and type 2 binding sites of N-recognins.
Whereas the binding of a monovalent molecule is mainly deter-
minedby the ligand’s binding affinity, the overall avidity of amulti-
valent molecule to the target is affected not only by the affinity of
individual ligands but also by other parameters such as the char-
acteristics of the linkers connecting the individual ligands (Mam-
men et al., 1998; Krishnamurthy et al., 2006; Kitov and Bundle,
2003; Kiessling et al., 2000). As noted by Kitov and Bundle
(2003), the free energy of binding for a multivalent interaction






where DG0mono is the free energy of binding for the correspond-
ing monovalent interaction, n represents the number of ligands
that are bound to receptors, and DG0interaction contains contribu-
tions from the favorable and unfavorable effects of tethering. The
various factors that contribute to DG0interaction are illustrated in
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The term ½ðn 1Þ TDS0mono;trans+ rot is based on the assump-
tion that the unfavorable translational and rotational entropy of
binding is approximately the same for a multivalent interaction
as for a monovalent one. The term ½ðn 1Þ DH0linker represents
the change in enthalpy due to interactions between the linker
and the target. The term ½ðn 1Þ TDS0conf represents the loss
of conformational entropy of the linkers following binding of the122 Chemistry & Biology 16, February 27, 2009 ª2009 Elsevier Ltd All rights reserved
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butions from cooperativity—the influence of one binding event
on subsequent events. The final term is a statistical factor based
on the degeneracy (Un) for the multivalent ligand-receptor
complex (Kitov and Bundle, 2003).
The above discussion can be used to guide the design of high
avidity multivalent or divalent ligands by focusing on the various
contributions to DG0interaction. For instance, as noted by Krishna-
murthy et al. (2006), the magnitude of the contribution due to
‘‘entropic enhancement,’’ ½ðn 1Þ TDS0mono;trans+ rot, might be
reduced by enthalpy/entropy compensation (EEC), because
binding events with more favorable enthalpies of binding are
associated with more unfavorable translational and rotational




TDS0mono;trans+ rot = c DH
0
mono (3)
where c is a constant (0 < c < 1). Collectively, Equations 2 and 3
suggest that for a constant DG0mono, the highest-avidity multiva-
lent ligands will be generated from monovalent ligands that bind
with the most favorable enthalpy, DH0mono.
The avidity of a multivalent ligand is influenced not only by the
choice of monovalent ligand, but also by the choice of linker.
Equation 2 suggests that the use of a rigid linker might be
optimal, as it would lower the conformational entropy penalty
½ðn 1Þ TDS0conf; however, a rigid linker might also result in
unfavorable interactions between the linkers or ligands and the
receptor. By contrast, a flexible linker would facilitate multivalent
bindingwithout steric obstruction, butmight result in a significant
loss in conformational entropy on binding. Models that assume
that bonds are free rotors predict severe losses in conforma-
tional entropy for flexible linkers (TDS0conf 0.7 kcal/mol per
freely rotating bond of a linker when it is bound at both ends)
(Krishnamurthy et al., 2007). Flexible linkers have, however,
been used successfully to design potent multivalent ligands
(Kramer and Karpen, 1998), and models based on effective
concentration (Ceff) predict a much smaller loss in conforma-
tional entropy on binding for long and flexible linkers thanmodels
based on the assumption that bonds are free rotors which
become completely restricted following multivalent binding
(Gargano et al., 2001; Diestler and Knapp, 2008; Krishnamurthy
et al., 2007). An effective strategy for the design of a multivalent
ligand might therefore be to connect the individual ligands by
a flexible linker that is significantly longer than the spacing
between the binding sites (Figures 1D–1F). We note that the prin-
ciples described above should be applicable for the design of
not only multivalent ligands but also homodivalent and heterodi-
valent ligands, including heterodivalent molecules that simulta-
neously target the type 1 and type 2 binding sites of N-recognins.
Although the above discussion focused primarily on thermo-
dynamics, the kinetics of interaction of multivalent ligands with
their targets are also of interest. Studies on the kinetics of multi-
valent interaction suggest that enhancements in avidity are
primarily due to decreases in the rates of dissociation (koff) of
the multivalent entities than due to increases in the rates of asso-
ciation (kon) (Mammen et al., 1998). There are also fundamental
differences between the dissociation of high-avidity multivalentChemistry & Biologcomplexes and the dissociation of high-affinity monovalent
complexes. For instance, the dissociation of multivalent com-
plexes occurs in stages, enabling the rate of dissociation to be
enhanced by the addition of sufficiently high concentrations of
competing monovalent ligand (Rao et al., 1998, 2000). As dis-
cussed above, these principles are generally applicable for
multivalent ligands as well as for homodivalent and heterodiva-
lent ligands.
The N-End Rule Pathway as an Intracellular
Model for Heterodivalent Inhibitors
The N-end rule pathway is a subset of the ubiquitin-proteasome
system (UPS), where recognition E3 components called N-rec-
ognins recognize type 1 and type 2 N-terminal residues of
substrates as part of degrons (N-degrons). Recent proteomic
studies identified four N-recognins containing the 70-residue
UBR box that functions as a substrate recognition domain for
type 1 and type 2N termini.We introduce theN-end rule pathway
to those who are interested in designing multivalent inhibitors for
intracellular pathways.
The Ubiquitin-Proteasome System
Ubiquitin is a 76-residue protein whose conjugation to other
proteins regulates a variety of biological processes (Varshavsky,
1997). Ub-dependent proteolysis involves themarking of a target
protein through covalent conjugation of Ub to an internal Lys
residue of a substrate, which is mediated by the E1-E2-E3 enzy-
matic cascade (Figure 2). E1 is the ATP-dependent Ub-acti-
vating enzyme, which forms a high-energy thioester bond
between the C-terminal Gly of Ub and a specific Cys of E1.
The activated Ub is trans-esterified to a Cys residue of an E2
enzyme. E3 recognizes a substrate’s degradation signal (degron)
and conjugates, as a complex with E2, Ub to the 3-amino group
of a Lys residue of a substrate protein. Repeated conjugation of
Ub results in a polyubiquitylated substrate that is recognized by
the proteolytic machinery of the UPS, the 26S proteasome
(Figure 2). In mammals, more than 500 Ub ligases mediate poly-
ubiquitylation of substrates through the recognition of degrons.
Degradation of certain substrates require an additional compo-
nent, E4, which binds short Ub chains and allows the formation
of longer chains.
The Structure and Components of the N-End
Rule Pathway
N-recognins recognize a set of basic (type 1; Arg, Lys, and His)
and bulky hydrophobic (type 2; Phe, Tyr, Trp, Leu, and Ile)
N-terminal residues as a degradation determinant (Bachmair
et al., 1986; Tasaki et al., 2005) (Figure 3A). In addition to
N-terminal residues, a functional N-degron requires an internal
Lys residue (the site of poly-Ub chain formation) and a character-
istic conformational feature appropriate for ubiquitylation. A
destabilizing N-terminal residue can be created by modifying
a pre-N-degron (Asn, Gln, Cys, Asp, or Glu) through an enzy-
matic cascade (Kwon et al., 2000, 2001, 2002). In mammals,
N-terminal asparagine (Asn) and glutamine (Gln) are conditionally
destabilizing through deamidation into aspartate (Asp) and gluta-
mate (Glu), which are respectively mediated by two distinct
amidohydrolases (Grigoryev et al., 1996; Kwon et al., 2000).
N-terminal Asp and Glu are arginylated by ATE1-encoded
R-transferase, a universal eukaryotic posttranslational modifica-
tion that creates the type 1 substrate Arg (Kwon et al., 1999a).y 16, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 123
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for Oxygen and Nitric Oxide
N-terminal arginylation requires Arg from Arg-tRNAArg of the
protein synthesis machinery, defining a tRNA-dependent Ub
system (Varshavsky, 1996). In contrast to S. cerevisiae, in
mammal, N-terminal cysteine (Cys) as well as Asp and Glu is
conditionally destabilizing through arginylation (Kwon et al.,
2002). However, in contrast to Asp and Glu, arginylation of
N-terminal Cys requires oxidation prior to arginylation (Lee
et al., 2005; Hu et al., 2005). In the presence of O2 (or its deriva-
tives) and NO, Cys is oxidized into CysO2(H) or CysO3(H), which
is recognized by ATE1, perhaps based on the structural similarity
to Asp. ATE1-deficient embryos die associated with defects in
cardiac development and angiogenesis (Kwon et al., 2002),
which was later attributed to failure to degrademultiple regulator
of G protein signaling (RGS) proteins (RGS4, RGS5, and RGS16)
(Lee et al., 2005; Hu et al., 2005). Following the cleavage of
N-terminal Met by Met aminopeptidases (MetAPs), Cys-2 of
these RGS proteins is N-terminally exposed and subsequently
undergoes oxidation and arginylation to produce the destabiliz-
ing residue Arg (Figure 3B). Because RGS4 and RGS5 play a crit-
ical role in Gq-dependent proliferation and signaling in cardio-
myocytes and vascular smooth muscle cells, respectively, it
has been proposed that the Ub system targeting these RGS
proteins controls homeostasis in cardiovascular signaling by
sensing O2 and NO (Lee et al., 2005). In addition to these RGS
proteins, it has been reported that numerous proteins can be ar-
ginylated at N-terminal or internal residues (Karakozova et al.,
Figure 2. The Ubiquitin-Proteasome
System
The substrates are ubiquitylated through multiple
rounds of a linear reaction catalyzed by E1, E2,
and E3. Shown as an example is the N-end rule
pathway.
2006; Wong et al., 2007). Thus, the failure
in nondegradable arginylation might also
contribute to cardiovascular null pheno-
types in ATE1-deficient embryos.
Creation of the N-Degron
Because newly synthesized proteins bear
N-terminal Met in eukaryotes (fMet in
prokaryotes), a functional N-degron
must be created by a posttranslational
modification (Tasaki and Kwon, 2007).
One way to create an N-end rule
substrate is to expose the second residue
at the N-terminus by MetAPs, which re-
moves the N-terminal Met when the
second residue is either Val, Gly, Pro,
Ala, Ser, Thr, or Cys (Lee et al., 2005;
Kendall and Bradshaw, 1992) (Figure 3B).
Among these, Cys can be converted into
a primary destabilizing residue through
oxidation and arginylation, whereas the
rest of the residues are stabilizing.
Indeed, studies have shown that N-de-
grons can be created via the removal of
N-terminal Met when the second residue is Cys (Lee et al.,
2005; Hu et al., 2005; Karakozova et al., 2006). The mammalian
genome encodes at least 502 proteins bearing an N-terminal
Met-Cys sequence (Y. Jiang and Y.T.K., unpublished data); it
remains to be tested how many of these produce N-degrons
after exposing Cys-2 at the N-terminus. Another way to create
an N-degron is via an endoproteolytic cleavage of a long-lived
polypeptide, which produces a short-lived C-terminal fragment
bearing a destabilizing N-terminal residue (Figure 3C). Intracel-
lular endopeptidases (e.g., caspases, separases, and calpains)
can create a C-terminal fragment bearing a tertiary or secondary
destabilizing N-terminal residue (Asn, Gln, Cys, Asp, or Glu in
mammals) or a primary destabilizing residue (Arg, Lys, His,
Leu, Phe, Trp, Tyr, or Ile in mammals).
Physiological Substrates and Functions
of the N-End Rule Pathway
In addition to RGS proteins, several proteins are known to be tar-
geted by the N-end rule pathway. In Drosophila melanogaster,
caspase-dependent cleavage of DIAP1 produces a C-terminal
fragment with the N-terminal Asn (Ditzel et al., 2003), which is
subsequently deamidated into the second destabilizing residue
Asp. In S. cerevisiae, the cohesin component SCC1 is cleaved
by separase at the metaphase-to-anaphase transition to
produce a C-terminal fragment bearing the destabilizing residue
Arg, which is indispensable for chromosome stability (Rao et al.,
2001). The N-end rule pathway is known to control half-lives of
several viral and bacterial proteins that are exposed in the cyto-
plasm of the host cell during the life cycle. The HIV-1 integrase,124 Chemistry & Biology 16, February 27, 2009 ª2009 Elsevier Ltd All rights reserved
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(A) The mammalian N-end rule pathway.
(B and C) The creation of destabilizing N-terminal residues through the removal of N-terminal Met (B) or the endoproteolytic cleavage of a protein (C).produced from the Gag-Pol precursor, catalyzes the insertion of
viral genome into host chromosome (Pommier et al., 2005). The
integrase, bearing the type 2 destabilizing residue Phe, is
degraded in mammalian cells by the N-end rule pathway (Mulder
and Muesing, 2000; Tasaki et al., 2005). The bacterium Listeria
monocytogenes is a life-threatening pathogen that infects the
cytosol of host cells through the activity of a pore-forming toxin,
listeriolysin O. Because of its potential cytotoxicity, the activity of
this virulence factor is controlled in part through ubiquitylation by
the N-end rule pathway (Schnupf et al., 2007). N-recognins
recognize not only N-degrons but also internal degrons
embedded in the substrate’s body. The latter class of substrates
includes S. cerevisiae CUP9 (a transcriptional repressor of the
peptide transporter PTR2), S. cerevisiae GPA1 (the Ga subunit
that controls signal transduction during mating), andmammalian
c-Fos (reviewed in Tasaki and Kwon, 2007).
Heterovalent Inhibitors of the N-End Rule Pathway
To explore the model of heterovalent interaction targeting an
intracellular pathway, Lee et al. (2008) recently designed the het-
erodivalent molecule RF-C11 whose type 1 and type 2 ligands
bind to multiple N-recognins. Heterovalent interaction to N-rec-
ognins was demonstrated to be an efficient way to control the
function of this posttranslational modification pathway in vitro
and in mammalian cells, such as cardiomyocytes. RF-C11 is
a prototype compound in which each of four replaceableChemistry & Biolocomponents can be further optimized in affinity, stability, and
cell permeability. The techniques described here are likely to
be useful for finding and developing multivalent compounds
that modulate the function of other intracellular pathways
in vitro and in vivo.
The N-Recognin Family as a Target of Heterodivalent
Molecules
Known mammalian N-recognins, termed UBR1, UBR2, UBR4,
and UBR5, are characterized by the UBR box, a 70-residue
zinc finger-like domain that functions as a general substrate
binding domain (Kwon et al., 1998; Tasaki et al., 2005) (Figure 4).
The UBR box provides a structural element for binding to
N-termini, in which specific residues in the UBR box (for type
1) or the N-domain (for type 2) provide substrate selectivity
through interaction with the side group of an N-terminal residue
(Tasaki and Kwon, 2007; Tasaki et al., 2009). UBR-box-contain-
ing fragments of UBR1 exhibit moderate affinity and high selec-
tivity to destabilizing N-terminal residues with Kd of 1.6–3.4 mM
(Xia et al., 2008; Tasaki et al., 2009). This moderate affinity allows
an appropriate balance between substrate selectivity and enzy-
matic processivity, ensuring both selective binding to a substrate
and rapid dissociation from the N terminus for an optimal rate of
polyubiquitylation.
Mammalian genome encodes at least seven UBR box
proteins, termed UBR1 through UBR7 (Tasaki et al., 2005). It
has been proposed that the UBR box acts as a receptor for smallgy 16, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 125
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2 ligands as part of a small molecule-modulated feedbackmech-
anism (Tasaki et al., 2007). UBR box proteins are generally
heterogeneous in size and sequence but contain, with the
exception of UBR4, specific signatures unique to E3s or
a substrate recognition subunit of the E3 complex (Figure 4A).
UBR1 and UBR2 are 200 kDa RING-finger E3s with 46% simi-
larity that form E3-E2 complexes with the Ub conjugating
enzyme HR6A or HR6B and exhibit similar enzymatic specific-
ities to N-degrons (Kwon et al., 2001; Tasaki et al., 2005; An
et al., 2006). Mutations in human UBR1 cause Johanson-Bliz-
zard syndrome (JBS; OMIM 243800), an autosomal recessive
disorder characterized by exocrine pancreatic insufficiency
and multiple malformations (Zenker et al., 2005). UBR1-deficient
mice also develop JBS-like phenotypes, including pancreatic
exocrine insufficiency (Zenker et al., 2005). Regardless of
biochemical similarity between UBR1 and UBR2, UBR2-defi-
cient mice exhibit distinct phenotypes: male-specific infertility
and female-specific lethality (Kwon et al., 2003). Weakly homol-
ogous to UBR1 and UBR2, 213 kDa UBR3 does not exhibit
affinity to N-degrons (Tasaki et al., 2007). UBR3 is prominently
expressed in sensory nervous cells critical for five major senses
(smell, touch, vision, hearing, and taste), and UBR3-deficient
neonatal pups die associated with anosmia (Tasaki et al.,
2007). 570 kDa UBR4 can bind to type 1 and type 2 N termini,
interacts with E7 oncoprotein and retinoblastoma protein, and
has been implicated in anchorage-independent growth and
cellular transformation (DeMasi et al., 2005). The functions of
other UBR proteins are discussed in Tasaki and Kwon (2007).
Design of the Heterodivalent Inhibitor RF-C11
of the N-Recognin Family
Taking advantage of the two-site architecture of N-recognin,
Kwon et al. (1999b) tested whether coexpression of two meta-
Figure 4. The UBR Box Protein Family
(A) A schematic diagram of UBR box proteins.
UBR indicates UBR box; RING, RING finger;
CRD, cysteine-rich domain; HECT, HECT domain;
PHD, plant homeodomain finger; UAIN, UBR-
specific autoinhibitory domain.
(B) A sequence alignment of the UBR boxes from
four species. Shown are the 70 amino acid
regions where conserved Cys and His residues
are highlighted (cyan). m indicatesMus musculus;
d,D.melanogaster; a,A. thaliana; sc,S. cerevisiae.
bolically stabilized N-end rule substrates,
Arg-bgal (type 1) and Leu-bgal (type 2),
would competitively inhibit degradation
of short-lived substrates in S. cerevisiae.
In a bgal tetramer, two N termini of each
dimer are spatially close, exposed, and
oriented to the same direction so that
one heterodimer bearing N-terminal Arg
and Leu is expected to be present in
a bgal tetramer. Although moderate in
efficacy, this proof-of-concept inhibitor
was demonstrated to inhibit the N-end
rule pathway.
Based on the protein-based heterodivalent inhibitor, Lee et al.
(2008) designed and characterized the synthetic heterovalent
inhibitor RF-C11, whose two different ligands bind to two binding
sites of the N-recognin family (Figure 5). RF-C11 was synthe-
sized as one of the model compounds, L1L2-Cn, which are
composed of four replaceable components: ligand (L1L2), linker
(Cn), core (lysine), and tag (e.g., biotin) (Figure 5A). The amino
acid lysine was chosen as the core component because it has
trifunctional groups, among which 3-amine and a-amine are
conjugated to two identical hydrocarbon chain linkers. In RF-
C11, two C11 hydrocarbon chains were conjugated to the type
1 substrate Arg and the type 2 substrate Phe. Two homodivalent
compounds, RR-C11 (bearing Arg at its termini) and FF-C11
(bearing Phe at its termini), were synthesized to compare heter-
odivalent versus homodivalent interactions. The structural
control GV-C11, with the stabilizing residues Gly and Val at its
termini, was synthesized to evaluate the potential interaction of
the linkers (Figure 5B). The linker length is an important param-
eter in heterovalent interaction. As the structures of N-recognins
were unknown, the guanidium group of Arg and the phenyl group
of Phe were designed to be45 A˚ apart to simultaneously reach
the entire binding pocket of the UBR-box-like domain, which
was deduced from the crystal structure of mouse zinc finger
protein 665 (Lee et al., 2008). When the direct interaction of
L1L2-C11 to N-recognins was evaluated, the reactive carboxylic
acid end of the core component was conjugated by a tag, biotin.
Inhibition of the N-End Rule Pathway Using
Heterovalent Interaction to N-Recognins
Polyubiquitylation involves an enzymatic cascade comprising
E1, E2, E3, and the proteasome, in which crosstalk between
E3-substrate interaction spatiotemporally modulates the meta-
bolic stability of a short-lived protein. Accordingly, various
assays are needed to verify biochemical and functional interac-
tion of a small molecule to the N-end rule pathway (Kwon et al.,126 Chemistry & Biology 16, February 27, 2009 ª2009 Elsevier Ltd All rights reserved
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itory efficacy of a small molecule on the degradation of an N-end
rule substrate that is expressed in transcription-translation
coupled reticulocyte lysates; this provides parameters concern-
ing an empirical binding event (e.g., IC50) rather than the actual
affinity. Model N-end rule substrates can be created by cotrans-
lational cleavage of a Ub-protein fusion by deubiquitylating
enzymes, which yields a set of proteins bearing either type 1,
type 2, or stabilizing residues (Bachmair et al., 1986). Using
Arg-nsP4 (type 1) and Tyr-nsP4 (type 2) as model substrates,
Lee et al. (2008) observed that the type 1 dipeptide Arg-Ala in-
hibited degradation of the type 1 substrate Arg-nsP4 with IC50
of 283 mM but showed no efficacy for the type 2 substrate.
Reciprocally, the type 2 dipeptide Trp-Ala inhibited degradation
of the type 2 substrate Tyr-nsP4 (IC50, 21 mM) but not type 1
substrates. In contrast to monovalent compounds, RF-C11 in-
hibited both type 1 and type 2 substrates and, moreover, with
significantly higher efficacy (IC50, 16 mM for Arg-nsP4; 2.7 mM
for Tyr-nsP4). RF-C11 also showed significantly higher efficacy
compared with type 1 homodivalent RR-C11 (67 mM for Arg-
nsP4) and type 2 homodivalent FF-C11 (151 mM for Tyr-nsP4).
The activity of these L1L2-C11 compounds should be specific
to ligands as the structural control GV-C11 did not affect the
degradation. The possibility that the enhanced efficacy of RF-
C11 is due to allosteric conformational change of binding sites
Figure 5. The Heterodivalent Inhibitor RF-C11 and its Control
Compounds
(A) A space-filling model of RF-C11.
(B) Structures of RF-C11 and its control compounds. Terminal moieties are
indicated by colored background.Chemistry & Biologwas ruled out because mixtures of monovalent or homodivalent
compounds did not give significantly additive effects. To further
verify the effect of L1L2-C11 on the E3 activity of N-recognins,
Lee et al. (2008) showed that RF-C11 inhibits in vitro ubiquityla-
tion of N-end rule substrates with higher efficacy than homodiva-
lent compounds, that RF-C11 directly binds to a 50 kDa UBR-
box-containing fragment of UBR1, and that RF-C11 can pull
downmultiple endogenous N-recognins from rat testes extracts.
These results provide experimental evidence that heterodivalent
interaction to multiple N-recognins, in the midst of the mamma-
lian proteome, leads to inhibition of both type 1 and type 2 N-end
rule activities with higher efficacy compared with homodivalent
or monovalent interaction.
Maly et al. (2000) showed that a heterodivalent inhibitor,
composed of carbazole and catechol units linked by a flexible
alkane chain, bound to the c-Src kinase with the heterodivalent
IC50 of 0.064 mM, compared with the monovalent IC50 of
40 mM. Rao and Whitesides (1997) reported an enhancement
factor of 103 for homodivalent vancomycin and D-Ala-D-Ala
interaction. A relatively moderate enhancement factor of
RF-C11 heterovalent interaction can be mainly attributed to the
linker length and the ligand affinity to targets, if the off-target
interaction of the linker and ligands with themselves or with other
cellular macromolecules is ignored. As far as two ligands can
reach their target binding sites, a shorter linker is generally favor-
able thermodynamically; a shorter linker is expected to result in
a lower conformational entropic penalty on binding and a higher
value of effective concentration (Ceff). Ceff can be better ex-
plained, in particular for biologists, by the enhanced local
concentration of the ligands near the binding sites. Specifically,
during RF-C11 interaction, the bound Phe ligand to the type 2
site will partially constrain the unbound Arg ligand of the same
molecule within the hemisphere of radius equivalent to the linker
length, and thereby increases the local Arg concentration in the
proximity of the type 1 site. This will increase the probability of
Arg binding to the type 1 site. Reciprocally, the bound Arg,
whose binding has been facilitated by the bound Phe, in turn
increases the local Phe concentration in the proximity of the
type 2 site, further facilitating the Phe interaction to N-recognin.
This mutual enhancement of local ligand concentrations is
inversely correlated to the linker length, until the linker matches
the distance between two targets (Figures 1D–1F). This was
indeed experimentally observed with serial RF-Cn compounds
with shorter linkers (S.M.S., R.B., and Y.T.K., unpublished
data). The enhancement in potency obtained by using divalent
ligands is determined by not only the linker length but also by
the affinity of the ligands for their targets. Lee et al. (2008) found
that the ligand Phe, linked to a nonproteinaceous C11 hydro-
carbon chain in homodivalent FF-C11, exhibited much lower
inhibitory efficacy than the dipeptide Phe-Ala that is thought to
have Kd of low micromolar (Xia et al., 2008; Tasaki et al., 2009).
Thus, the other way to increase heterovalent avidity is by
enhancing the affinity of ligands, in particular the type 2 ligand,
to the target. Recently, various Phe derivatives were synthesized
and, a few of them were demonstrated to have higher inhibitory
efficacy against N-recognins than the Phe ligand of RF-C11
(S.M.S., R. Kuruba, and Y.T.K., unpublished data). Future work
will involve the design of amino acid derivatives with high affinity
to achieve high monovalent enthalpy of binding and optimizationy 16, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 127
Chemistry & Biology
Reviewof the linker length to achieve the maximal effective concentra-
tion without contributing significantly to the conformational
entropic penalty.
In Vivo Application of Heterovalent Inhibitors
Because the N-end rule pathway is mediated by a set of func-
tionally overlapping N-recognins, pharmaceutical inhibitors are
a useful tool to dissect the function of the entire pathway. Dipep-
tides bearing destabilizing N-terminal residues have been widely
used as competitive inhibitors in biochemical and physiological
analyses of the N-end rule pathway (Tasaki and Kwon, 2007).
However, these monovalent compounds are at best weak inhib-
itors, often used at millimolar concentrations, and, moreover, are
highly unstable due to the cleavage of the peptide bond by endo-
peptidases (Kwon et al., 2001), making it ineffective for mamma-
lian cells. Lee et al. (2008) demonstrated that RF-C11 is capable
of inhibiting the degradation of a physiological N-end rule
substrate, RGS4, in mammalian cells. The in vivo efficacy of
RF-C11 and its derivatives opens up an avenue to new physio-
logical functions of the N-end rule pathway. Using RF-C11 and
its structural control, Lee et al. (2008) revealed a cell-autono-
mous function of the N-end rule pathway in cardiac proliferation
and hypertrophy (Figure 6). It has been shown that mouse
embryos lacking ATE1 R-transferase die associated with defects
in cardiac development and angiogenesis, which was also
observed in animals lacking two downstream E3 components,
UBR1 and UBR2 (Kwon et al., 2002; An et al., 2006). In an
attempt to determine a cell-autonomous function of these
components, Lee et al. (2008) found that RF-C11 significantly
reduces cardiac proliferation and hypertrophy in primary cardio-
myocytes isolated from mouse embryonic hearts (Figure 6). In
contrast, the structural control GV-C11 exhibited no detectible
efficacy. In humans, myocardial hypertrophy, associated with
hypertension, cardiac valvular disease, or ischemia, is typically
followed by serious myocardial diseases that account for the
leading causes of death in Western society. As such, N-recog-
nins might be a therapeutic target for heterovalent inhibitors
to control pathophysiological conditions in cardiovascular
signaling.
The Ubiquitin-Proteasome Pathway as a Potential
Target for Multivalent Ligands
In addition to the N-end rule pathway, recent advances in struc-
tural understanding of the UPS components reveal several
potential targets for multivalent interaction. The 26S protea-
some, composed of the 19S regulatory particle and the 20S
core particle, is an abundant supracomplex with the concentra-
tion of 1–20 mg/mg soluble protein (Kuehn et al., 1986). The 19S
particle consists of the 9-protein ‘‘lid’’ that recognizes polyubi-
quitin and the 10-protein ‘‘base’’ with the ATPase activity that
binds to the a ring of the 20S core particle (Glickman et al.,
1998). The 19S particle deubiquitylates, unfolds, and transfers
polyubiquitylated substrates into the 20S particle (Verma et al.,
2004). The 20S particle is a stack of four rings of heptameric
complexes composed of two different types of subunits;
a subunits are gatekeepers for the proteolytic core composed
of b subunits (Groll et al., 1997). Inside the 20S cylinder, subunits
b1, b2, and b5 of two stacked b-rings expose their proteolytically
active sites to execute postglutamyl peptide hydrolysing,
trypsin-like and chymotrypsin-like activities, respectively (Groll128 Chemistry & Biology 16, February 27, 2009 ª2009 Elsevier Ltd Aand Clausen, 2003). The multimeric nature of the 20S particle,
the availability of various monovalent inhibitors with distinct
inhibitory mechanisms, and the short distances of catalytic sites
of the b-subunits, ranging from 28 to 64 A˚, together make its
internal surface as an ideal supramolecular array for heterodiva-
lent interaction. One feasible approach would be to link two
nonoverlapping monovalent inhibitors in a way that does not
interfere with the activity of the monovalent molecules and
ensures the simultaneous binding to two binding sites of the
b-subunits. Various small molecule inhibitors have been devel-
oped to target the 26S proteasome, mostly the inner surface of
the 20S particle, with IC50 values ranging from low nanomolar
to 100 mM (Kisselev, 2008). Velcade (bortezomib), a dipeptide
boronate with affinity to the N-terminal threonine hydroxyl group
of b5, has been approved by the Food andDrug Administration in
2003 for the treatment of multiple myeloma and mantle cell
lymphoma and in 2006 for the treatment of mantle cell lymphoma
(Kisselev, 2008). Salinosporamide A (NPI-0052), a b-lactone
derivative, inhibits all three peptidase activities of the 20S
particle and is in phase 1 clinical trials for the patients with solid
tumors and lymphomas resistant to Velcade treatment (Chauhan
Figure 6. The Control of Cardiac Signaling and Hypertrophy by
RF-C11
Shown is a model where RGS4, RGS5, and RGS16 are cotranslationally
degraded through serial Cys-2 modifications (see the main text). In this model,
the heterovalent interaction of RF-C11 to the N-recognin family inhibits the
degradation of these RGS proteins in cardiomyocytes, leading to their meta-
bolic stabilization and inactivation of G protein signaling.ll rights reserved
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categorized into aldehydes (tyropeptin A, fellutamide B, and
MG132), epoxyketones (epoxomicin, eponemycin, and carfilzo-
mib), vinyl sulfones (NLVS and ZLVS), and macrocyclic vinyl
ketones (syringolin A and glidobactin A) (Kisselev, 2008).
Although less well characterized than the 20S particle, the
p53-MDM2 interface is also worthy of attention (reviewed in
Do¨mling, 2008). The tumor suppressor p53 is a transcription
factor that plays a critical role in maintaining genomic integrity.
The level of p53 is tightly controlled by the Ub ligase MDM2
that binds p53 with Kd of 60–700 nM to mediate ubiquitylation
and to inhibit the transcriptional activity of p53. Mutations of
p53 are involved in approximately half of all known cancers,
and overexpression of MDM2 is found in many cancers as
well, including soft tissue sarcomas, osteosarcomas, and breast
tumors (Momand et al., 1998). In contrast to most other protein-
protein interactions where the large, undefined interface area
hampers the design of small molecule inhibitors, X-ray structures
indicate that the p53-MDM2 interface is confined to a pretty
small area of 809 and 660 (A˚)2 for p53 and MDM2, respectively
(Chene, 2003). Accordingly, various small molecule inhibitors
of p53 have been designed as anticancer agents, including
Nutlins, Ke-43, 5-deazaflavin derivatives, rhodamine derivatives,
and tricyclic derivatives (Berg, 2008), some of which show high
activity to induce apoptosis and inhibit cancer cell proliferation.
Thus, the well-characterized interface and the availability of
various monovalent inhibitors associated with clinical impor-
tance together make the p53-MDM2 interface a potential target
for heterodivalent interaction.
Concluding Remarks
The purpose of this review was to introduce the N-end rule
pathway and related intracellular signaling pathways as a model
for multivalent molecules. Intracellular proteins communicate
with other proteins or ligands in part through structurally and
functionally distinct domains such as the UBR box of the
N-end rule pathway or the F-box of the SCF E3 pathway, the
latter being an adaptor between a substrate and the SKP1/
CUL1 E3 complex (Bai et al., 1996). As demonstrated with the
UBR box, multivalent ligands targeting multiple sites located in
one or multiple domains might provide a tool to probe protein-
protein interactions and to identify new physiological functions
of a specific signaling pathway. This approach will be particularly
useful when a mechanistically distinct pathway is mediated by
a set of functionally overlapping proteins with the same domain,
such as the N-end rule pathway and the SCF-type E3 systems.
Some proteins form a transient or long-lasting complex with
a multivalent array, such as the 26S proteasome or the APC E3
complex (Frescas and Pagano, 2008). A multivalent molecule
targeting two subunits might be utilized to probe their assembly,
disassembly, and spatial localization within the complex, to
probe their interactions with peripheral interactors, or to selec-
tively inhibit the complex’s activities. The concept of multiva-
lency has been recently adopted in FBDD, and we are now
witnessing a number of compounds entering into phase 2 clinical
trials (Congreve et al., 2008). The concept of heterodivalency
also might be exploited in drug repositioning (Ashburn and
Thor, 2004), an approach to develop new use for an existing
drug, in which two appropriate drugs are linked to yield higherChemistry & Bioloefficacy or lower adverse effects, provided that tethering of the
drugs does not adversely affect the pharmacokinetic properties.
Future strategy includes identifying appropriate target mole-
cules, which will require advances in structural and functional
understanding on biological interactions. The linkers and ligands
will need to be optimized in cell penetration, solubility, and in vivo
stability. New thermodynamic models might be needed to better
explain the interactions of the linkers and ligands with them-
selves and other molecules within the cell.
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